ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

Phase 2

Active, not recruiting

Conditions: Spinal Cord Injury (SCI)

Interventions: Drug: Placebo
Drug: Elezanumab

First Posted Date: 2020-03-04

Last Posted Date: 2024-06-25

Lead Sponsor: AbbVie

Target Recruit Count: 60

Registration Number: NCT04295538

Locations: 🇺🇸
Thomas Jefferson University Hospital /ID# 215460, Philadelphia, Pennsylvania, United States
🇯🇵
National Hospital Organization Murayama Medical Center /ID# 223492, Musashimurayama-shi, Tokyo, Japan
🇯🇵
Japan Organization of Occupational Health and Safety Spinal Injuries Centre /ID# 224141, Iizuka-shi, Japan

and more 38 locations

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Bimatoprost SR
Drug: LUMIGAN

First Posted Date: 2020-02-26

Last Posted Date: 2023-06-08

Lead Sponsor: AbbVie

Target Recruit Count: 37

Registration Number: NCT04285580

Locations: 🇺🇸
Coastal Research Associates /ID# 232798, Roswell, Georgia, United States
🇺🇸
Scott and Christie and Associates /ID# 232747, Cranberry Township, Pennsylvania, United States
🇺🇸
The Eye Research Foundation /ID# 232694, Newport Beach, California, United States

and more 3 locations

Expanded Access to Elezanumab

Conditions: Acute Spinal Cord Injury (SCI)
Acute Ischemic Stroke

First Posted Date: 2020-02-20

Last Posted Date: 2024-04-03

Lead Sponsor: AbbVie

Registration Number: NCT04278235

A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

Phase 4

Completed

Conditions: Hypogonadism

Interventions: Drug: AndroGel 1.62%

First Posted Date: 2020-02-18

Last Posted Date: 2022-12-15

Lead Sponsor: AbbVie

Target Recruit Count: 246

Registration Number: NCT04274894

Locations: 🇺🇸
Innovative Research of West Florida /ID# 216364, Clearwater, Florida, United States
🇺🇸
Loretto Hospital.Affnity Clinical Research Institute /ID# 216884, Chicago, Illinois, United States
🇺🇸
Tristar Clinical Investigations PC /ID# 216944, Philadelphia, Pennsylvania, United States

and more 42 locations

A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Phase 1

Terminated

Conditions: Non Small Cell Lung Cancer
Cancer

Interventions: Drug: Venetoclax
Drug: Pembrolizumab

First Posted Date: 2020-02-18

Last Posted Date: 2021-02-11

Lead Sponsor: AbbVie

Target Recruit Count: 2

Registration Number: NCT04274907

Locations: 🇺🇸
Arizona Oncology Associates, PC-HOPE (Rudasill) /ID# 216984, Tucson, Arizona, United States
🇺🇸
St Jude Hospital dba St Joseph /ID# 212360, Santa Rosa, California, United States
🇺🇸
Icri /Id# 217071, Whittier, California, United States

and more 36 locations

A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Phase 1

Terminated

Conditions: Breast Cancer
Cancer

Interventions: Drug: Venetoclax
Drug: Capecitabine

First Posted Date: 2020-02-18

Last Posted Date: 2020-10-29

Lead Sponsor: AbbVie

Target Recruit Count: 4

Registration Number: NCT04274933

Locations: 🇺🇸
Greenville Health System Cance /ID# 216059, Greenville, South Carolina, United States
🇩🇪
Universitaetsklinik Heidelberg /ID# 214679, Heidelberg, Baden-Wuerttemberg, Germany
🇵🇷
GCM Medical Group PSC - Hato Rey /ID# 216904, San Juan, Puerto Rico

and more 15 locations

A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers

Phase 1

Terminated

Conditions: Non Small Cell Lung Cancer
Cancer
Acute Myeloid Leukemia (AML)

Interventions: Drug: ABBV-184

First Posted Date: 2020-02-17

Last Posted Date: 2022-09-08

Lead Sponsor: AbbVie

Target Recruit Count: 14

Registration Number: NCT04272203

Locations: 🇯🇵
National Cancer Center Hospital East /ID# 216467, Kashiwa-shi, Chiba, Japan
🇮🇱
Tel Aviv Sourasky Medical Center /ID# 222749, Tel Aviv-Yafo, Tel-Aviv, Israel
🇫🇷
Hopital Saint-Andre /ID# 224218, Bordeaux, France

and more 14 locations

An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiveness of Upadacitinib as Monotherapy or in Combination With MTX in Adult Participants With Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis (RA)

First Posted Date: 2020-02-13

Last Posted Date: 2023-01-26

Lead Sponsor: AbbVie

Target Recruit Count: 534

Registration Number: NCT04267536

Locations: 🇩🇪
Rheumahaus Studien GbR, Potsdam, DE /ID# 218430, Potsdam, Brandenburg, Germany
🇩🇪
Stille, Hanover, DE /ID# 218429, Hannover, Germany
🇩🇪
Praxis K. Pagel /ID# 218714, Hoppegarten, Germany

and more 49 locations

A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wrist Actigraphy Data In Adult Healthy Volunteers And Participants With Atopic Dermatitis (AD)

Phase 1

Terminated

Conditions: Atopic Dermatitis

Interventions: Device: Wrist Actigraphy Device
Device: Sleep Headband

First Posted Date: 2020-02-10

Last Posted Date: 2022-02-15

Lead Sponsor: AbbVie

Target Recruit Count: 16

Registration Number: NCT04262791

Locations: 🇺🇸
PPD Clinical Research Unit /ID# 217010, Orlando, Florida, United States
🇺🇸
Acpru /Id# 217345, Grayslake, Illinois, United States
🇺🇸
Univ Rochester Med Ctr /ID# 217490, Rochester, New York, United States

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Phase 1

Completed

Conditions: Ulcerative Colitis (UC)
Crohn's Disease

Interventions: Drug: Risankizumab
Drug: Cytochrome P450 (CYP) Substrates

First Posted Date: 2020-02-05

Last Posted Date: 2024-07-01

Lead Sponsor: AbbVie

Target Recruit Count: 20

Registration Number: NCT04254783

Locations: 🇺🇸
University Clinical Research /ID# 216823, DeLand, Florida, United States
🇺🇸
Southern California Res. Ctr. /ID# 216257, Coronado, California, United States
🇺🇸
Clinical Trials of Texas, Inc /ID# 216277, San Antonio, Texas, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy